Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

November 18, 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

November 18, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

November 13, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

November 15, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Village-Level Intervention Nets Big BP Control Gains in Rural China

News Conference News AHA 2021

Village-Level Intervention Nets Big BP Control Gains in Rural China

November 13, 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

News Conference News AHA 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

November 17, 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

News Conference News AHA 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Michael O'Riordan

November 15, 2020

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.